Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

Citations Over TimeTop 1% of 2003 papers

Abstract

Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for <10% of patients. Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections.

Related Papers

• → Successsful Voriconazole Treatment of Disseminated Fusarium Infection in an Immunocompromised Patient(2003)79 cited
• CNS-aspergillosis: are there new treatment options?(2003)
• → Case report: invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation(2003)2 cited
• [Experience with voriconazole in invasive aspergillosis].(2003)